A sequential approach combining neoadjuvant and adjuvant chemotherapy with surgery markedly boosts survival for high-risk colorectal liver metastasis patients.
- Patients receiving neoadjuvant chemotherapy had a median progression-free survival of 1.1 years versus 0.6 years for surgery-first patients (p<0.001).
- Overall survival was better in the neoadjuvant group: 5.2 years compared to 4.3 years (p=0.044).
Completing the entire treatment sequence correlates with the best outcomes.
- Matched analysis confirmed these findings, indicating a clear benefit to neoadjuvant therapy before surgery.
Journal Article by Kobayashi K, Ono Y (…) Takahashi Y et 8 al. in Surg Today
© 2025. The Author(s) under exclusive licence to Springer Nature Singapore Pte Ltd.